Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03123588
Title Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

essential thrombocythemia

Therapies

Ruxolitinib

Anagrelide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.